Resveratrol: a relevant pharmacological approach for the treatment of metabolic syndrome?

Related Experiment Video

Updated: Jun 9, 2026

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment
10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

Jean-Louis Beaudeux1, Valérie Nivet-Antoine, Philippe Giral

  • 1EA 4466 Stress cellulaire: physiopathologie, stratégies nutritionnelles et innovations thérapeutiques, Faculté de Pharmacie Paris Descartes, hôpital Charles Foix, APHP, Paris, France.

Current Opinion in Clinical Nutrition and Metabolic Care
|September 9, 2010
PubMed
Abstract

Insights

Resveratrol, a natural compound, activates sirtuins, offering a potential new drug class to combat metabolic syndrome, obesity, and diabetes by targeting key cellular pathways.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Diseases

Background:

  • Metabolic syndrome increases risks for cardiovascular disease and type 2 diabetes.
  • Metabolic syndrome and caloric restriction exhibit opposing pathophysiological pathways.
  • Sirtuin activation presents a potential therapeutic strategy for metabolic syndrome.

Purpose of the Study:

  • To review the therapeutic applications of resveratrol and sirtuin activators.
  • To explore their role in managing insulin resistance and obesity, key features of metabolic syndrome.

Main Methods:

  • Literature review of studies on resveratrol, sirtuins, and metabolic syndrome.
  • Analysis of resveratrol's regulatory actions on AMP kinase and sirtuin-1.
  • Discussion of pharmacological approaches targeting sirtuin-1 activity.

Main Results:

  • Resveratrol acts as a natural activator of sirtuins, particularly sirtuin-1.
  • It modulates AMP kinase and sirtuin-1 pathways.
  • This positions resveratrol as a lead compound for a new class of drugs.

Conclusions:

  • Resveratrol and sirtuin activators show therapeutic promise for metabolic syndrome.
  • They offer a strategy to treat or protect against obesity and diabetes.
  • Targeting sirtuin-1 activity is a key pharmacological approach.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...